Managed through the Foundation for the NIH, the Accelerating Medicines Partnership (AMP) "brings high-level government, industry, and non-profit foundation partners together to identify and validate the most promising biological targets for therapeutics." These organizations focus on four diseases—Alzheimer's disease, type 2 diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosusand. All AMP partners make the data and analyses they contribute publicly accessible to the broad biomedical community through an online portal. An executive committee of representatives from the NIH, participating industry leaders, the FDA, and non-profit organizations oversees the organization. Individual projects are overseen through steering committees for each of the disease areas, each committee containing representation from all partners. The AMP initiative combines public-private expertise and pooled data to reduce the time and cost of developing biomarkers for disease treatment. The project attempts to overcome fragmentation in the pharmaceutical industry and improve innovation in drug therapy. By combining data the AMP portal can find new drug targets and reduce wasteful repetition of testing found when companies work in silos.